Kymera Therapeutics (KYMR) Cash from Investing Activities (2019 - 2026)

Kymera Therapeutics (KYMR) has 8 years of Cash from Investing Activities data on file, last reported at -$142.8 million in Q1 2026.

• On a quarterly basis, Cash from Investing Activities fell 393.82% year-over-year to -$142.8 million in Q1 2026; TTM through Mar 2026 was -$712.5 million, a 2766.69% decrease from a year earlier, with the FY2025 full-year figure at -$521.1 million, down 28.95% from the prior year.
• Cash from Investing Activities for Q1 2026 stood at -$142.8 million, up from -$394.4 million in the prior quarter.
• Over the last five years, Cash from Investing Activities for KYMR reached as high as $81.8 million in Q2 2022 and fell as low as -$394.4 million in Q4 2025.
• Historically, Cash from Investing Activities has averaged -$53.4 million across 5 years, with a median of $19.0 million in 2023.
• Across the five-year window, Cash from Investing Activities tumbled 1444.81% in 2024 and soared 283.72% in 2025, its largest moves.
• Year by year, Cash from Investing Activities stood at -$49.7 million in 2022, then surged by 138.16% to $19.0 million in 2023, then soared by 261.8% to $68.6 million in 2024, then sank by 675.19% to -$394.4 million in 2025, then jumped by 63.78% to -$142.8 million in 2026.
• Per Business Quant data, the three most recent Cash from Investing Activities figures were -$142.8 million in Q1 2026, -$394.4 million in Q4 2025, and -$235.3 million in Q3 2025.